Nasdaq:US$19.47 (+0.02) | HKEX:HK$30.95 (+0.00) | AIM:£3.11 (+0.03)
搜索
新聞中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科學出版物 | 2013-04-06

AACR 2013: HMPL-504 (savolitinib), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer